Home Homocysteine in relation to cognitive performance in pathological and non-pathological conditions
Article
Licensed
Unlicensed Requires Authentication

Homocysteine in relation to cognitive performance in pathological and non-pathological conditions

  • Charlotte E. Teunissen , Martin P. J. van Boxtel , Jellemer Jolles , Jan de Vente , Fred Vreeling , Frans Verhey , Chris H. Polman , Christine D. Dijkstra and Henk J. Blom
Published/Copyright: September 21, 2011
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 43 Issue 10

Abstract

Elevated serum homocysteine has been associated with increased risk of Alzheimer's disease. Furthermore, elevated homocysteine levels are related to cognitive dysfunction in the elderly. The aim of the present study was to explore the disease specificity of the relation between serum total homocysteine levels and cognitive function. For this, we summarize data from several studies on homocysteine levels in both normal and pathological conditions performed in our laboratories and evaluate possible mechanisms of effects of elevated homocysteine levels in the central nervous system. Total homocysteine levels were measured in serum of: 1) healthy aging individuals; 2) patients with Alzheimer's and Parkinson's disease and patients with other cognitive disorders; and 3) patients with multiple sclerosis. Increased serum homocysteine concentration was related to worse cognitive performance over a 6-year period in the normal aging population (r=−0.36 to −0.14, p<0.01 for the Word learning tests; r=0.76, p<0.05 for the Stroop Colored Word test). Homocysteine was only increased in patients with Parkinson's disease on L-Dopa therapy (18.9 vs. 16.5μmol/L in healthy controls), and not in dementia patients. Homocysteine was elevated in patients with progressive multiple sclerosis (15.0μmol/L, n=39, compared to 12.0 μmol/L in 45 controls) and correlated to both cognitive and motor function (r=−0.33 and −0.33, p<0.05, respectively). The relationship between homocysteine and cognitive function in non-pathological and pathological situations indicates that changes in its levels may play a role in cognitive functioning in a broad spectrum of conditions.

Keywords: aging; cognition; dementia; homocysteine; multiple sclerosis
Corresponding author: Dr. Charlotte E. Teunissen, Molecular Cell Biology and Immunology, VU University Medical Center, FdG, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands Phone: +31-20-4448076, Fax: +31-20-4448081,

References

1. Regland B, Abrahamsson L, Gottfries CG, Magnus E. Vitamin B12 analogues, homocysteine, methylmalonic acid, and transcobalamins in the study of vitamin B12 deficiency in primary degenerative dementia. Dementia 1990; 1:272–7.Search in Google Scholar

2. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55:1449–55.10.1001/archneur.55.11.1449Search in Google Scholar PubMed

3. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346:476–83.10.1056/NEJMoa011613Search in Google Scholar PubMed

4. Budge M, Johnston C, Hogervorst E, de Jager C, Milwain E, Iversen SD, et al. Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann NY Acad Sci 2000; 903:407–10.10.1111/j.1749-6632.2000.tb06392.xSearch in Google Scholar PubMed

5. Kalmijn S, Launer LJ, Lindemans J, Bots ML, Hofman A, Breteler MM. Total homocysteine and cognitive decline in a community-based sample of elderly subjects: the Rotterdam Study. Am J Epidemiol 1999; 150:283–9.10.1093/oxfordjournals.aje.a010000Search in Google Scholar PubMed

6. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Hyper-homocysteinemia associated with poor recall in the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2001; 73:927–33.10.1093/ajcn/73.5.927Search in Google Scholar PubMed

7. Duthie SJ, Whalley LJ, Collins AR, Leaper S, Berger K, Deary IJ. Homocysteine, B vitamin status, and cognitive function in the elderly. Am J Clin Nutr 2002; 75:908–13.10.1093/ajcn/75.5.908Search in Google Scholar PubMed

8. Riggs KM, Spiro A III, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996; 63:306–14.10.1093/ajcn/63.3.306Search in Google Scholar PubMed

9. McCaddon A, Hudson P, Davies G, Hughes A, Williams JH, Wilkinson C. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord 2001; 12:309–13.10.1159/000051275Search in Google Scholar PubMed

10. Teunissen CE, Blom AH, Van Boxtel MP, Bosma H, de Bruijn C, Jolles J, et al. Homocysteine: a marker for cognitive performance? A longitudinal follow-up study. J Nutr Health Aging 2003; 7:153–9.Search in Google Scholar

11. Jolles J, Houx PJ, van Boxtel MP, Ponds RW. The Maastricht Aging Study. Determinants of cognitive aging. Maastricht: Neuropsych Publishers, 1995.Search in Google Scholar

12. van Boxtel MP, Gaillard C, Houx PJ, Buntinx F, de Leeuw PW, Jolles J. Is nondipping in 24 h ambulatory blood pressure related to cognitive dysfunction? J Hypertens 1998; 16:1425–32.10.1097/00004872-199816100-00005Search in Google Scholar PubMed

13. Kado DM, Karlamangla AS, Huang MH, Troen A, Rowe JW, Selhub J, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med 2005; 118:161–7.10.1016/j.amjmed.2004.08.019Search in Google Scholar PubMed

14. Chertkow H. Mild cognitive impairment. Curr Opin Neurol 2002; 15:401–7.10.1097/00019052-200208000-00001Search in Google Scholar

15. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004; 62:1972–6.10.1212/01.WNL.0000129504.60409.88Search in Google Scholar

16. Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 2004; 80:114–22.Search in Google Scholar

17. Ariogul S, Cankurtaran M, Dagli N, Khalil M, Yavuz B. Vitamin B(12), folate, homocysteine and dementia: are they really related? Arch Gerontol Geriatr 2005; 40:139–46.10.1016/j.archger.2004.07.005Search in Google Scholar

18. O'Suilleabhain P, Diaz-Arrastia R. Levodopa elevates homocysteine: is this a problem? Arch Neurol 2004; 61:633–4.10.1001/archneur.61.5.633Search in Google Scholar

19. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004; 63:886–91.10.1212/01.WNL.0000137886.74175.5ASearch in Google Scholar

20. Bleich S, Otto M, Zerr I, Kropp S, Kretzschmar HA, Wiltfang J. Creutzfeldt-Jakob disease and homocysteine levels in plasma and cerebrospinal fluid. Gerontology 2005; 51:142–4.10.1159/000082200Search in Google Scholar

21. Teunissen CE, Lutjohann D, von Bergmann K, Verhey F, Vreeling F, Wauters A, et al. Combination of serum markers related to several mechanisms in Alzheimer's disease. Neurobiol Aging 2003; 24:893–902.10.1016/S0197-4580(03)00005-8Search in Google Scholar

22. Benedict RH, Weinstock-Guttman B, Fishman I, Sharma J, Tjoa CW, Bakshi R. Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol 2004; 61:226–30.10.1001/archneur.61.2.226Search in Google Scholar PubMed

23. Amato MP, Bartolozzi ML, Zipoli V, Portaccio E, Mortilla M, Guidi L, et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment. Neurology 2004; 63:89–93.10.1212/01.WNL.0000129544.79539.D5Search in Google Scholar

24. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41:685–91.10.1212/WNL.41.5.685Search in Google Scholar PubMed

25. Bobholz JA, Rao SM. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003; 16:283–8.10.1097/01.wco.0000073928.19076.84Search in Google Scholar

26. Savettieri G, Messina D, Andreoli V, Bonavita S, Caltagirone C, Cittadella R, et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol 2004; 251:1208–14.10.1007/s00415-004-0508-ySearch in Google Scholar

27. Teunissen CE, Dijkstra CD, Polman CH. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 2005; 4:32–41.10.1016/S1474-4422(04)00964-0Search in Google Scholar

28. Goodkin DE, Jacobsen DW, Galvez N, Daughtry M, Secic M, Green R. Serum cobalamin deficiency is uncommon in multiple sclerosis. Arch Neurol 1994; 51:1110–4.10.1001/archneur.1994.00540230048011Search in Google Scholar

29. Reynolds EH. Multiple sclerosis and vitamin B12 metabolism. J Neuroimmunol 1992; 40:225–30.10.1016/0165-5728(92)90137-ASearch in Google Scholar

30. Besler HT, Comoglu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 2003; 6:189–96.10.1080/1028415031000115945Search in Google Scholar

31. Vrethem M, Mattsson E, Hebelka H, Leerbeck K, Osterberg A, Landtblom AM, et al. Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid. Mult Scler 2003; 9:239–45.10.1191/1352458503ms918oaSearch in Google Scholar

32. Kado DM, Bucur A, Selhub J, Rowe JW, Seeman T. Homocysteine levels and decline in physical function: MacArthur Studies of Successful Aging. Am J Med 2002; 113:537–42.10.1016/S0002-9343(02)01269-XSearch in Google Scholar

33. Selley ML, Close DR, Stern SE. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 2002; 23:383–8.10.1016/S0197-4580(01)00327-XSearch in Google Scholar

34. Robert K, Vialard F, Thiery E, Toyama K, Sinet PM, Janel N, et al. Expression of the cystathionine beta synthase (CBS) gene during mouse development and immunolocalization in adult brain. J Histochem Cytochem 2003; 51:363–71.10.1177/002215540305100311Search in Google Scholar PubMed

35. Kennedy BP, Bottiglieri T, Arning E, Ziegler MG, Hansen LA, Masliah E. Elevated S-adenosylhomocysteine in Alzheimer brain: influence on methyltransferases andcognitive function. J Neural Transm 2004; 111:547–67.10.1007/s00702-003-0096-5Search in Google Scholar

36. Refsum H, Ueland PM, Nygard O, Vollset SE. Homo-cysteine and cardiovascular disease. Annu Rev Med 1998; 49:31–62.10.1146/annurev.med.49.1.31Search in Google Scholar

37. Vermeer SE, van Dijk EJ, Koudstaal PJ, Oudkerk M, Hofman A, Clarke R, et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 2002; 51:285–9.10.1002/ana.10111Search in Google Scholar

38. Sengupta S, Wehbe C, Majors AK, Ketterer ME, DiBello PM, Jacobsen DW. Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J Biol Chem 2001; 276:46896–904.10.1074/jbc.M108451200Search in Google Scholar

39. Reis EA, Zugno AI, Franzon R, Tagliari B, Matte C, Lammers ML, et al. Pretreatment with vitamins E and C prevent the impairment of memory caused by homocysteine administration in rats. Metab Brain Dis 2002; 17:211–7.10.1023/A:1019982223034Search in Google Scholar

40. Wyse AT, Zugno AI, Streck EL, Matte C, Calcagnotto T, Wannmacher CM, et al. Inhibition of Na(+),K(+)-ATPase activity in hippocampus of rats subjected to acute administration of homocysteine is prevented by vitamins E and C treatment. Neurochem Res 2002; 27:1685–9.10.1023/A:1021647329937Search in Google Scholar

41. Kubova H, Folbergrova J, Mares P. Seizures induced by homocysteine in rats during ontogenesis. Epilepsia 1995; 36:750–6.10.1111/j.1528-1157.1995.tb01611.xSearch in Google Scholar

42. Fykse EM, Iversen EG, Fonnum F. Inhibition of L-glutamate uptake into synaptic vesicles. Neurosci Lett 1992; 135:125–8.10.1016/0304-3940(92)90151-VSearch in Google Scholar

43. Matte C, Monteiro SC, Calcagnotto T, Bavaresco CS, Netto CA, Wyse AT. In vivo and in vitro effects of homocysteine on Na+, K+-ATPase activity in parietal, prefrontal and cingulate cortex of young rats. Int J Dev Neurosci 2004; 22:185–90.10.1016/j.ijdevneu.2004.05.007Search in Google Scholar PubMed

44. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 2004; 109:369–74.10.1161/01.CIR.0000109492.65802.ADSearch in Google Scholar PubMed

45. Chung YH, Hong JJ, Shin CM, Joo KM, Kim MJ, Cha CI. Immunohistochemical study on the distribution of homocysteine in the central nervous system of transgenic mice expressing a human Cu/Zn SOD mutation. Brain Res 2003; 967:226–34.10.1016/S0006-8993(03)02238-8Search in Google Scholar

46. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000; 106:483–91.10.1172/JCI8342Search in Google Scholar

47. Schlaich MP, John S, Jacobi J, Lackner KJ, Schmieder RE. Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients. Atherosclerosis 2000; 153:383–9.10.1016/S0021-9150(00)00412-3Search in Google Scholar

48. Zhang F, Slungaard A, Vercellotti GM, Iadecola C. Super-oxide-dependent cerebrovascular effects of homocysteine. Am J Physiol 1998; 274:R1704–11.10.1152/ajpregu.1998.274.6.R1704Search in Google Scholar

49. Lee SJ, Kim KM, Namkoong S, Kim CK, Kang YC, Lee H, et al. Nitric oxide inhibition of homocysteine-induced human endothelial cell apoptosis by down-regulation of p53-dependent Noxa expression through the formation of S-nitrosohomocysteine. J Biol Chem 2005; 280:5781–8.10.1074/jbc.M411224200Search in Google Scholar

50. Kim WK. S-Nitrosation ameliorates homocysteine-induced neurotoxicity and calcium responses in primary culture of rat cortical neurons. Neurosci Lett 1999; 265:99–102.10.1016/S0304-3940(99)00212-8Search in Google Scholar

51. D'Emilia DM, Lipton SA. Ratio of S-nitrosohomocyst(e)ine to homocyst(e)ine or other thiols determines neurotoxicity in rat cerebrocortical cultures. Neurosci Lett 1999; 265:103–6.10.1016/S0304-3940(99)00210-4Search in Google Scholar

52. Contestabile A, Monti B, Ciani E. Brain nitric oxide and its dual role in neurodegeneration/neuroprotection: understanding molecular mechanisms to devise drug approaches. Curr Med Chem 2003; 10:2147–74.10.2174/0929867033456792Search in Google Scholar PubMed

53. O'Brien NC, Charlton B, Cowden WB, Willenborg DO. Inhibition of nitric oxide synthase initiates relapsing remitting experimental autoimmune encephalomyelitis in rats, yet nitric oxide appears to be essential for clinical expression of disease. J Immunol 2001; 167:5904–12.10.4049/jimmunol.167.10.5904Search in Google Scholar PubMed

54. Keilhoff G, Fansa H, Wolf G. Nitric oxide synthase, an essential factor in peripheral nerve regeneration. Cell Mol Biol (Noisy-le-grand) 2003; 49:885–97.Search in Google Scholar

55. Kruman , II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000; 20:6920–6.10.1523/JNEUROSCI.20-18-06920.2000Search in Google Scholar

56. Axelrod J. Methylation reactions in the formation and metabolism of catecholamines and other biogenic amines. Pharmacol Rev 1966; 18:95–113.Search in Google Scholar

Published Online: 2011-9-21
Published in Print: 2005-10-1

©2005 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Homocysteine research – where do we stand and where are we going?
  2. Hyperhomocysteinemia and arteriosclerosis: historical perspectives
  3. Homocysteine and heart failure: a review of investigations from the Framingham Heart Study
  4. Homocysteine and vascular disease in diabetes: a double hit?
  5. Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia
  6. Effects of homocysteine on vascular and tissue adenosine: a stake in homocysteine pathogenicity?
  7. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease
  8. Carotid narrowing degree and plasma thiol levels in carotid endarterectomy patients
  9. Impairment of homocysteine metabolism in patients with retinal vascular occlusion and non-arteritic ischemic optic neuropathy
  10. Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation
  11. Hyperhomocysteinemia and macromolecule modifications in uremic patients
  12. Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients
  13. Vitamin B12 deficiency is the dominant nutritional cause of hyperhomocysteinemia in a folic acid-fortified population
  14. Homocysteine, folic acid and vitamin B12 in relation to pre- and postnatal health aspects
  15. Evaluation of the technical performance of novel holotranscobalamin (holoTC) assays in a multicenter European demonstration project
  16. A laboratory algorithm with homocysteine as the primary parameter reduces the cost of investigation of folate and cobalamin deficiency
  17. Betaine: a key modulator of one-carbon metabolism and homocysteine status
  18. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis
  19. Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro
  20. Homocysteine in relation to cognitive performance in pathological and non-pathological conditions
  21. Homocysteine and B vitamins in mild cognitive impairment and dementia
  22. Homocysteine, type 2 diabetes mellitus, and cognitive performance: The Maine-Syracuse Study
  23. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions
  24. Homocysteine – a newly recognised risk factor for osteoporosis
  25. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women
  26. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality
  27. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance
  28. Concentrations of homocysteine, related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status
  29. Asymmetric dimethylarginine, homocysteine and renal function – is there a relation?
  30. Interactions between folate and aging for carcinogenesis
  31. The potential cocarcinogenic effect of vitamin B12 deficiency
  32. The vegetarian lifestyle and DNA methylation
https://doi.org/10.1515/CCLM.2005.190
Keywords for this article
aging; cognition; dementia; homocysteine; multiple sclerosis

Articles in the same Issue

  1. Homocysteine research – where do we stand and where are we going?
  2. Hyperhomocysteinemia and arteriosclerosis: historical perspectives
  3. Homocysteine and heart failure: a review of investigations from the Framingham Heart Study
  4. Homocysteine and vascular disease in diabetes: a double hit?
  5. Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia
  6. Effects of homocysteine on vascular and tissue adenosine: a stake in homocysteine pathogenicity?
  7. Anti-N-homocysteinylated protein autoantibodies and cardiovascular disease
  8. Carotid narrowing degree and plasma thiol levels in carotid endarterectomy patients
  9. Impairment of homocysteine metabolism in patients with retinal vascular occlusion and non-arteritic ischemic optic neuropathy
  10. Hyperhomocysteinaemia in chronic kidney disease: focus on transmethylation
  11. Hyperhomocysteinemia and macromolecule modifications in uremic patients
  12. Hyperhomocysteinemia and response of methionine cycle intermediates to vitamin treatment in renal patients
  13. Vitamin B12 deficiency is the dominant nutritional cause of hyperhomocysteinemia in a folic acid-fortified population
  14. Homocysteine, folic acid and vitamin B12 in relation to pre- and postnatal health aspects
  15. Evaluation of the technical performance of novel holotranscobalamin (holoTC) assays in a multicenter European demonstration project
  16. A laboratory algorithm with homocysteine as the primary parameter reduces the cost of investigation of folate and cobalamin deficiency
  17. Betaine: a key modulator of one-carbon metabolism and homocysteine status
  18. Molecular targeting by homocysteine: a mechanism for vascular pathogenesis
  19. Anti-inflammatory compound resveratrol suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells in vitro
  20. Homocysteine in relation to cognitive performance in pathological and non-pathological conditions
  21. Homocysteine and B vitamins in mild cognitive impairment and dementia
  22. Homocysteine, type 2 diabetes mellitus, and cognitive performance: The Maine-Syracuse Study
  23. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions
  24. Homocysteine – a newly recognised risk factor for osteoporosis
  25. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women
  26. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality
  27. Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance
  28. Concentrations of homocysteine, related metabolites and asymmetric dimethylarginine in preeclamptic women with poor nutritional status
  29. Asymmetric dimethylarginine, homocysteine and renal function – is there a relation?
  30. Interactions between folate and aging for carcinogenesis
  31. The potential cocarcinogenic effect of vitamin B12 deficiency
  32. The vegetarian lifestyle and DNA methylation
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 12.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2005.190/html
Scroll to top button